Is the NCI MATCH trial a match for gynecologic oncology
作者： Kathleen N. Moore , Robert S. Mannel
DOI: 10.1016/J.YGYNO.2015.11.003
关键词: Precision Medicine Initiative 、 Gynecologic oncology 、 Bioinformatics 、 Medical physics 、 Clinical trial 、 Cancer 、 Review article 、 Precision medicine 、 Medicine 、 Targeted therapy 、 Tumor type
摘要: The Precision Medicine Initiative is an NCI driven program in cancer to generate the scientific evidence needed move concept of precision medicine into clinical practice. rapid development and widespread availability next generation sequencing other molecular interrogation tumors has heralded a new era knowledge about each individual's tumor at point time. In some instances, this information led therapeutic discoveries, most been uninformative or unclear significance. Molecular Analysis for Therapy Choice (MATCH) trial [NCT02465060] which screens features that may predict response drug with given mechanism action, multi-study, collaborative effort between many pharmaceutical companies begin clarify significance alterations not previously studied. This design recent appreciation certain driver mutations be common particular type are mutated diseases low frequency (<10%). mutations, testing utility targeted therapy requires screening large numbers patients. review article will discuss types novel designs launch MATCH.
gynecologiconcology-online.net
elsevier.com
sci-hub.se 参考文章(32)
Grant A. McArthur, Combination therapies to inhibit the RAF/MEK/ERK pathway in melanoma: we are not done yet Frontiers in Oncology. ,vol. 5, pp. 161- 161 ,(2015) , 10.3389/FONC.2015.00161
Asher Mullard, NCI-MATCH trial pushes cancer umbrella trial paradigm Nature Reviews Drug Discovery. ,vol. 14, pp. 513- 515 ,(2015) , 10.1038/NRD4694
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Mackiewicz, Daniil Stroiakovski, Michael Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion-Sileni, Kamil Drucis, Ivana Krajsova, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V Long, Keith Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D Rubin, Shonda M Little, Dirk Schadendorf, None, Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib The New England Journal of Medicine. ,vol. 372, pp. 30- 39 ,(2015) , 10.1056/NEJMOA1412690
Daniel V.T. Catenacci, Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Molecular Oncology. ,vol. 9, pp. 967- 996 ,(2015) , 10.1016/J.MOLONC.2014.09.011
Diana P. English, Dana M. Roque, Luisa Carrara, Salvatore Lopez, Stefania Bellone, Emiliano Cocco, Ileana Bortolomai, Peter E. Schwartz, Thomas Rutherford, Alessandro D. Santin, HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor Gynecologic Oncology. ,vol. 131, pp. 753- 758 ,(2013) , 10.1016/J.YGYNO.2013.08.033
Alexi A. Wright, Brooke E. Howitt, Andrea P. Myers, Suzanne E. Dahlberg, Emanuele Palescandolo, Paul Van Hummelen, Laura E. MacConaill, Melina Shoni, Nikhil Wagle, Robert T. Jones, Charles M. Quick, Anna Laury, Ingrid T. Katz, William C. Hahn, Ursula A. Matulonis, Michelle S. Hirsch, Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix Cancer. ,vol. 119, pp. 3776- 3783 ,(2013) , 10.1002/CNCR.28288
Douglas A Levine, Cancer Genome Atlas Research Network Genome sequencing centres: Broad Institute Getz Gad 1 Gabriel Stacey B. 1 Cibulskis Kristian 1 Lander Eric 1 Sivachenko Andrey 1 Sougnez Carrie 1 Lawrence Mike 1, Washington University in St Louis Kandoth Cyriac 2 Dooling David 2 Fulton Robert 2 Fulton Lucinda 2 Kalicki-Veizer Joelle 2 McLellan Michael D. 2 O’Laughlin Michelle 2 Schmidt Heather 2 Wilson Richard K. 2 Ye Kai 2 Ding Li 2 Mardis Elaine R. 2, University of Southern California & Johns Hopkins Baylin Stephen B. 21 Bootwalla Moiz S. 22 Lai Phillip H. 22 Triche Jr Timothy J. 22 Van Den Berg David J. 22 Weisenberger Daniel J. 22 Laird Peter W. 22 Shen Hui 22, Institute for Systems Biology Reynolds Sheila M. 23 Shmulevich Ilya 23, University of California, Santa Cruz/Buck Institute Benz Stephen 28 Goldstein Ted 28 Haussler David 28 Ng Sam 28 Szeto Christopher 28 Stuart Joshua 28 Benz Christopher C. 29 Yau Christina 29, Tissue source sites: Asterand Barnabas Nandita 37 Berry-Green Charlenia 37 Blanc Victoria 37 Boice Lori 38 Button Michael 37 Farkas Adam 37 Green Alex 37 MacKenzie Jean 37 Nicholson Dana 37, British Columbia Cancer Agency Kalloger Steve E. 39 40 Blake Gilks C. 39 40, Cedars-Sinai Medical Center Karlan Beth Y. 41 Lester Jenny 41 Orsulic Sandra 41, Christiana Care Borowsky Mark 42 Cadungog Mark 42 Czerwinski Christine 42 Huelsenbeck-Dill Lori 42 Iacocca Mary 42 Petrelli Nicholas 42 Rabeno Brenda 42 Witkin Gary 42, Cureline Nemirovich-Danchenko Elena 43 Potapova Olga 43 Rotin Daniil 43, Duke University Berchuck Andrew 44, Gynecologic Oncology Group Birrer Michael 45 DiSaia Phillip 46 Monovich Laura 47, International Genomics Consortium Curley Erin 48 Gardner Johanna 48 Mallery David 48 Penny Robert 48, Mayo Clinic Dowdy Sean C. 49 Winterhoff Boris 49 Dao Linda 50 Gostout Bobbie 49 Meuter Alexandra 49 Teoman Attila 49, Memorial Sloan-Kettering Cancer Center Dao Fanny 51 Olvera Narciso 51 Bogomolniy Faina 51 Garg Karuna 52 Soslow Robert A. 52 Levine Douglas A. 51, NN Blokhin Russian Cancer Research Center Abramov Mikhail 53, Ontario Tumour Bank Bartlett John MS 54 Kodeeswaran Sugy 54 Parfitt Jeremy 55, St Petersburg Academic University Moiseenko Fedor 56, University Health Network Clarke Blaise A. 57, University of Hawaii Goodman Marc T. 58 59 Carney Michael E. 58 Matsuno Rayna K. 58, University of North Carolina Fisher Jennifer 38 Huang Mei 38 Kimryn Rathmell W. 15 Thorne Leigh 38 Van Le Linda 38, University of Pittsburgh Dhir Rajiv 60 Edwards Robert 60 Elishaev Esther 60 Zorn Kristin 60, University of Texas MD Anderson Cancer Center Broaddus Russell 31, Washington University School of Medicine Goodfellow Paul J. 36 61 Mutch David 61, Data coordination centre Ayala Brenda 62 Chu Anna L. 62 Jensen Mark A. 62 Kothiyal Prachi 62 Pihl Todd D. 62 Pontius Joan 62 Pot David A. 62 Snyder Eric E. 62 Srinivasan Deepak 62 Kahn Ari B. 62, Project team: National Cancer Institute Mills Shaw Kenna R. 67 Sheth Margi 67 Davidsen Tanja 67 Eley Martin L. Ferguson Greg 68 69 Demchok John A. 67 Yang Liming 67, National Human Genome Research Institute Guyer Mark S. 70 Ozenberger Bradley A. 70 Sofia Heidi J. 70, None, Integrated genomic characterization of endometrial carcinoma Nature. ,vol. 497, pp. 67- 73 ,(2013) , 10.1038/NATURE12113
Marianne Tuefferd, Jérôme Couturier, Frédérique Penault-Llorca, Anne Vincent-Salomon, Philippe Broët, Jean-Paul Guastalla, Djelila Allouache, Martin Combe, Béatrice Weber, Eric Pujade-Lauraine, Sophie Camilleri-Broët, HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients PLOS ONE. ,vol. 2, ,(2007) , 10.1371/JOURNAL.PONE.0001138
John W. Park, Minetta C. Liu, Douglas Yee, Angela DeMichele, Laura van 't Veer, Nola Hylton, Fraser Symmans, Meredith B. Buxton, A. Jo Chien, Amy Wallace, Michelle Melisko, Richard Schwab, Judy Boughey, Debashish Tripathy, Hank Kaplan, Rita Nanda, Stephen Chui, Kathy S. Albain, Stacy Moulder, Anthony Elias, Julie E. Lang, Kirsten Edminston, Donald Northfelt, David Euhus, Qamar Khan, Julia Lyandres, Sarah E. Davis, Christina Yau, Ashish Sanil, Laura J. Esserman, Donald A. Berry, Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL Cancer Research. ,vol. 74, ,(2014) , 10.1158/1538-7445.AM2014-CT227
Michael J. Birrer, Ovarian Cancer: Targeting the Untargetable American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. ,vol. 34, pp. 13- 15 ,(2014) , 10.14694/EDBOOK_AM.2014.34.13